Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2020
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid TumorsTaofeek K Owonikoko, R Donald Harvey, Bradley Carthon, et al.
Cancer|August 20, 2021
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 studyJames J Harding, Tsai-Sheng Yang, Yen-Yang Chen, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2026
ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Cancer|October 18, 2018
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapyMehmet A Bilen, Dylan J Martini, Yuan Liu, et al.
Investigational New Drugs|February 7, 2019
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trialsDylan J Martini, Yuan Liu, Julie M Shabto, et al.
Molecular Cancer|March 14, 2025
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal AdenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Cancer|October 25, 2019
Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trialsDylan J Martini, Meredith R Kline, Yuan Liu, et al.
The Oncologist|March 13, 2020
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with ImmunotherapyMehmet Asim Bilen, Dylan J Martini, Yuan Liu, et al.
JCO Precision Oncology|January 15, 2026
Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyDaniel R Carrizosa, Michael Rothe, Pam K Mangat, et al.
Pageof 9